Clinical trial
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in…
NCT00388700 · Galectin Therapeutics Inc., Industry · Withdrawn
Key facts
| NCT number | NCT00388700 |
|---|---|
| Title | A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer |
| Official title | Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy |
| Lead sponsor | Galectin Therapeutics Inc., Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | GM-CT-01, 5-Fluorouracil, Leukovorin, bevacizumab |
| Enrollment | 0 |
| Start date | Oct 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Oct 17, 2006 |
| Last update posted | Feb 14, 2018 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: